The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures
Year: 2019
Type: article
Abstract: In comparison to batteries of standard neuropsychological tests, cognitive neuroscience tests may offer a more specific assessment of discrete neurobiological processes that may be aberrant in schizophrenia. However, more information regarding psychometric properties and correlations with standard neuropsychological tests and functional measures is warranted to establish their validity as treatment outcome measures. The N-back and AX-Continuous Performance Task (AX-CPT) are two promising cognitive neuroscience tests designed to measure specific components of working memory and contextual processing respectively. In the current study, we report the psychometric properties of multiple outcome measures from these two tests as well as their correlations with standard neuropsychological measures and functional capacity measures. The results suggest that while the AX-CPT and N-back display favorable psychometric properties, they do not exhibit greater sensitivity or specificity with functional measures than standard neurocognitive tests.
Source: Schizophrenia Research Cognition
Authors: Michael S. Kraus, James M. Gold, Deanna M. Barch, Trina M. Walker, Charlotte A. Chun, Robert W. Buchanan, John G. Csernansky, Donald C. Goff, Michael F. Green, L. Fredrik Jarskog, Daniel C. Javitt, David Kimhy, Jeffrey A. Lieberman, Joseph P. McEvoy, Raquelle I. Mesholam-Gately, Larry J. Seidman, M. Patricia Ball, Robert S. Kern, Robert P. McMahon, James Robinson, Stephen R. Marder, Richard S.E. Keefe
Institutions: Duke University, Duke Medical Center, University of Maryland, Baltimore, Washington University in St. Louis, Temple University, Northwestern University, Harvard University, Massachusetts General Hospital, University of California, Los Angeles, VA Desert Pacific Healthcare Network, University of North Carolina at Chapel Hill, Nathan Kline Institute for Psychiatric Research, New York University, Icahn School of Medicine at Mount Sinai, New York State Psychiatric Institute, Columbia University, Beth Israel Deaconess Medical Center
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,100
Funders: Eli Lilly and Company, Pfizer, Sanofi, Biogen, University of Southern California, Teva Pharmaceutical Industries, Montana State University, Sunovion, Indivior, Les Laboratories Pierre Fabre, GW Pharmaceuticals, Avanir Pharmaceuticals, Cerecor, Upsher-Smith, Astellas Pharma, Swedish Orphan Biovitrum, H. Lundbeck A/S, Akebia Therapeutics, Genentech, Allergan, Takeda Oncology, National Institute of Mental Health
Award: G575830593
OpenAlex ID: W2987494826